Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 16/20 | 0.64 |
| ▸ | KDM5C | P41229 | 10/20 | 0.64 |
| ▸ | KDM5A | P29375 | 7/20 | 0.64 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM4A | O75164 | 4/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16291539 | 0.91 | KDM5B (0.77) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716656 | 0.88 | KDM5B (0.59) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL16912751 | 0.85 | KDM5B (0.55) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL26862768 | 0.85 | KDM5A (0.46) | KDM5BKDM5CKDM5AKDM4CKDM4E | |
| SCHEMBL21716662 | 0.83 | KDM5B (0.84) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL26862784 | 0.81 | KDM5B (0.71) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716673 | 0.80 | KDM5B (0.82) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716663 | 0.78 | KDM5B (1.00) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716669 | 0.77 | KDM5B (0.67) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716677 | 0.77 | KDM5B (0.74) | KDM5BKDM5CKDM5AKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2020033377-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KDM5C 3/4885KDM5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.